Cargando…

Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms

Dipeptidyl peptidase 4 (DPP4) inhibitors are a class of antidiabetic medications that cause glucose-dependent increase in incretins in diabetic patients. One of the two incretins, glucagon-like peptide-1 (GLP-1), beside its insulinotropic activity, has been studied for extra pancreatic effects. Most...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zakaria, Esraa M., Tawfeek, Walaa M., Hassanin, Mohamed H., Hassaballah, Mohammed Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568460/ https://www.ncbi.nlm.nih.gov/pubmed/35945358 http://dx.doi.org/10.1007/s00210-022-02279-3

Ejemplares similares

DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors
por: Dicker, Dror
Publicado: (2011)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

From sequence analysis of DPP-4 to molecular docking based searching of its inhibitors
por: Alsamghan, Awad Saeed, et al.
Publicado: (2020)

The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy
por: Dietrich, Nadine, et al.
Publicado: (2016)

Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases
por: Kubo, Ayano, et al.
Publicado: (2020)

A Molecular Modeling Investigation of the Therapeutic Potential of Marine Compounds as DPP-4 Inhibitors
por: Antony, Priya, et al.
Publicado: (2022)

The potential effects of DPP‐4 inhibitors on cardiovascular system in COVID‐19 patients
por: Du, Hengzhi, et al.
Publicado: (2020)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
por: Liu, Jinglong, et al.
Publicado: (2014)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease
por: Schuetz, Charles Andy, et al.
Publicado: (2015)

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
por: Scheen, André J.
Publicado: (2018)

DPP4 as a Potential Candidate in Cardiovascular Disease
por: Chen, Si-Yu, et al.
Publicado: (2022)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study
por: Lin, Yi-Hsuan, et al.
Publicado: (2018)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

The Role of DPP4 Activity in Cardiovascular Districts: In Vivo and In Vitro Evidence
por: Pala, L., et al.
Publicado: (2013)

Acute myocardial infarction associated to DPP-4 inhibitors
por: Nunes, J P L, et al.
Publicado: (2014)

Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios
por: Gomez-Peralta, Fernando, et al.
Publicado: (2018)

DPP3: From biomarker to therapeutic target of cardiovascular diseases
por: Ye, Peng, et al.
Publicado: (2022)

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
por: Wang, Aiying, et al.
Publicado: (2012)

To the editor regarding article “Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study”
por: Mayer, Florian J., et al.
Publicado: (2018)

An update on preclinical models of hereditary haemorrhagic telangiectasia: Insights into disease mechanisms
por: Arthur, Helen M., et al.
Publicado: (2022)

Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study
por: Kim, Young-Gun, et al.
Publicado: (2016)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Andukuri, Radha, et al.
Publicado: (2009)

Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria
por: Haluzík, Martin, et al.
Publicado: (2013)

Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control
por: Kang, Seon Mee, et al.
Publicado: (2021)

THU287 Comparison Of Renal Protective Effects Between SGLT2 Inhibitors And DPP4 Inhibitors In Real-World Clinical Practice
por: Park, Hyeong-Kyu, et al.
Publicado: (2023)

Exercise and cardiovascular protection: Update and future
por: Xiao, Junjie, et al.
Publicado: (2021)

DPP-4 Inhibition and Neuroprotection: Do Mechanisms Matter?
por: Shannon, Richard P.
Publicado: (2013)

Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans
por: Cicero, Arrigo F., et al.
Publicado: (2010)

Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes
por: Vitale, Cristiana, et al.
Publicado: (2016)

DPP-IV Inhibitor–Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema
por: Ejikeme, Chidinma, et al.
Publicado: (2021)

Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
por: Lotfy, Mohamed, et al.
Publicado: (2011)

Novel Potent and Selective DPP-4 Inhibitors: Design, Synthesis and Molecular Docking Study of Dihydropyrimidine Phthalimide Hybrids
por: Mourad, Ahmed A. E., et al.
Publicado: (2021)

DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure
por: Koibuchi, Nobutaka, et al.
Publicado: (2014)

Cardiovascular outcomes of type 2 diabetic patients treated with DPP‑4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice
por: Bazo-Alvarez, Juan Carlos, et al.
Publicado: (2021)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_4mlk8oec8r29c489on4ocgh7dh